Immunization with M2e-Displaying T7 Bacteriophage Nanoparticles Protects against Influenza A Virus Challenge

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Hashemi, Hamidreza ^a   Pouyanfard, Somayeh ^b   Bandehpour, Mojgan ^c,d   Noroozbabaei, Zahra ^a   Kazemi, Bahram ^c,d   Saelens, Xavier ^e,f   Mokhtari Azad, Talat ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; IMMUNOGLOBULIN G; INFLUENZA VACCINE; NANOPARTICLE; T7 M2E INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIOPHAGE T7; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMULSION; FEMALE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VACCINATION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; T LYMPHOCYTE; TH1 CELL; VIRUS LOAD; VIRUS TITRATION;

ADJUVANTS, IMMUNOLOGIC; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, VIRAL; BACTERIOPHAGE T7; CELLS, CULTURED; FEMALE; FREUND'S ADJUVANT; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED BALB C; NANOPARTICLES; SPLEEN; T-LYMPHOCYTES; VACCINATION; VIRAL LOAD; VIRAL MATRIX PROTEINS;

FLU VACCINE; INFLUENZA A VIRUS; MAMMALIA; MUS; ORTHOMYXOVIRIDAE;

EID: 84866664372     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045765     Document Type: Article

References (75)

1. Aballea S, Chancellor J, Martin M, Wutzler P, Carrat F, et al. (2007) The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health 10: 98-116.
2. Clements ML, Betts RF, Tierney EL, Murphy BR, (1986) Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24: 157-160.
3. Couch RB, (1975) Assessment of immunity to influenza using artifical challenge of normal volunteers with influenza virus. Dev Biol Stand 28: 295-306.
4. Hobson D, Curry RL, Beare AS, Ward-Gardner A, (1972) The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70: 767-777.
5. Gething MJ, Bye J, Skehel J, Waterfield M, (1980) Cloning and DNA sequence of double-stranded copies of haemagglutinin genes from H2 and H3 strains elucidates antigenic shift and drift in human influenza virus. Nature 287: 301-306.
6. Jou WM, Verhoeyen M, Devos R, Saman E, Fang R, et al. (1980) Complete structure of the hemagglutinin gene from the human influenza A/Victoria/3/75 (H3N2) strain as determined from cloned DNA. Cell 19: 683-696.
7. Schotsaert M, De Filette M, Fiers W, Saelens X, (2009) Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 8: 499-508.
8. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, et al. (2011) Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29: 5145-5152.
9. Lamb RA, Choppin PW, (1981) Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology 112: 729-737.
10. Zebedee SL, Lamb RA, (1988) Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62: 2762-2772.
11. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR, (1990) Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64: 1375-1377.
12. Jackson DC, Tang XL, Murti KG, Webster RG, Tregear GW, et al. (1991) Electron microscopic evidence for the association of M2 protein with the influenza virion. Arch Virol 118: 199-207.
13. Park EK, Castrucci MR, Portner A, Kawaoka Y, (1998) The M2 ectodomain is important for its incorporation into influenza A virions. J Virol 72: 2449-2455.
14. Wang R, Song A, Levin J, Dennis D, Zhang NJ, et al. (2008) Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80: 168-177.
15. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, et al. (2010) Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 186: 1022-1031.
16. Denkers EY, Badger CC, Ledbetter JA, Bernstein ID, (1985) Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol 135: 2183-2186.
17. Heusser CH, Anderson CL, Grey HM, (1977) Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J Exp Med 145: 1316-1327.
18. Snapper CM, Paul WE, (1987) Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236: 944-947.
19. Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, et al. (2012) Universal vaccine against influenza virus: Linking TLR signaling to anti-viral protection. Eur J Immunol 42: 863-869.
20. Lamb RA, Zebedee SL, Richardson CD, (1985) Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40: 627-633.
21. Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, et al. (2006) Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3: 102.
22. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, et al. (1993) The influence of antigen organization on B cell responsiveness. Science 262: 1448-1451.
23. Chackerian B, Lowy DR, Schiller JT, (1999) Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A 96: 2373-2378.
24. Chackerian B, Lowy DR, Schiller JT, (2001) Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108: 415-423.
25. Kouskoff V, Lacaud G, Nemazee D, (2000) T cell-independent rescue of B lymphocytes from peripheral immune tolerance. Science 287: 2501-2503.
26. Zhao G, Lin Y, Du L, Guan J, Sun S, et al. (2010) An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 7: 9.
27. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, et al. (2003) Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21: 2616-2626.
28. Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, et al. (2008) Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 38: 114-126.
29. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-214.
30. Ionescu RM, Przysiecki CT, Liang X, Garsky VM, Fan J, et al. (2006) Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. J Pharm Sci 95: 70-79.
31. Jegerlehner A, Tissot A, Lechner F, Sebbel P, Erdmann I, et al. (2002) A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20: 3104-3112.
32. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, et al. (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5: 1157-1163.
33. Herrmann S, Leshem B, Lobel L, Bin H, Mendelson E, et al. (2007) T7 phage display of Ep15 peptide for the detection of WNV IgG. J Virol Methods 141: 133-140.
34. Tan GH, Yusoff K, Seow HF, Tan WS, (2005) Antigenicity and immunogenicity of the immunodominant region of hepatitis B surface antigen displayed on bacteriophage T7. J Med Virol 77: 475-480.
35. Franke ED, Corradin G, Hoffman SL, (1997) Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides. J Immunol 159: 3424-3433.
36. Morrot A, Cockburn IA, Overstreet M, Rodriguez D, Zavala F, (2006) Protective CD8+ T cells induced by malaria sporozoites do not undergo modulation of interleukin-7 receptor expression. Infect Immun 74: 2495-2497.
37. Adams MH (1959) Bacteriophages. New York: Interscience Publishers, Inc.
38. Jiang J, Abu-Shilbayeh L, Rao VB, (1997) Display of a PorA peptide from Neisseria meningitidis on the bacteriophage T4 capsid surface. Infect Immun 65: 4770-4777.
39. Aida Y, Pabst MJ, (1990) Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 132: 191-195.
40. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
41. Towbin H, Staehelin T, Gordon J, (1992) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. Biotechnology 24: 145-149.
42. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, et al. (2008) An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 283: 11382-11387.
43. Rosenberg A GK, Studier W, McCormick M, Berg J, Novy R, Mierendorf R. (1996) T7 Select phage display system: A powerful new protein display system based on bacteriophage T7. Novagen Newsletter: 1-6.
44. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, et al. (2008) Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26: 3395-3403.
45. Pejoski D, Zeng W, Rockman S, Brown LE, Jackson DC, (2010) A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol Cell Biol 88: 605-611.
46. Wu F, Huang JH, Yuan XY, Huang WS, Chen YH, (2007) Characterization of immunity induced by M2e of influenza virus. Vaccine 25: 8868-8873.
47. Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, et al. (2009) M2e-based universal influenza A vaccine. Vaccine 27: 6280-6283.
48. Jegerlehner A, Schmitz N, Storni T, Bachmann MF, (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172: 5598-5605.
49. Di Giovine M, Salone B, Martina Y, Amati V, Zambruno G, et al. (2001) Binding properties, cell delivery, and gene transfer of adenoviral penton base displaying bacteriophage. Virology 282: 102-112.
50. De Berardinis P, Sartorius R, Fanutti C, Perham RN, Del Pozzo G, et al. (2000) Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses. Nat Biotechnol 18: 873-876.
51. Fang J, Wang G, Yang Q, Song J, Wang Y, et al. (2005) The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model. Vaccine 23: 4860-4866.
52. Ulivieri C, Citro A, Ivaldi F, Mascolo D, Ghittoni R, et al. (2008) Antigenic properties of HCMV peptides displayed by filamentous bacteriophages vs. synthetic peptides. Immunol Lett 119: 62-70.
53. Gamage LN, Ellis J, Hayes S, (2009) Immunogenicity of bacteriophage lambda particles displaying porcine Circovirus 2 (PCV2) capsid protein epitopes. Vaccine 27: 6595-6604.
54. Gupta A, Onda M, Pastan I, Adhya S, Chaudhary VK, (2003) High-density functional display of proteins on bacteriophage lambda. J Mol Biol 334: 241-254.
55. Hayes S, Gamage LN, Hayes C, (2010) Dual expression system for assembling phage lambda display particle (LDP) vaccine to porcine Circovirus 2 (PCV2). Vaccine 28: 6789-6799.
56. Ren S, Fengyu, Zuo S, Zhao M, Wang X, et al. (2011) Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine. Vaccine 29: 5802-5811.
57. Ren SX, Ren ZJ, Zhao MY, Wang XB, Zuo SG, et al. (2009) Antitumor activity of endogenous mFlt4 displayed on a T4 phage nanoparticle surface. Acta Pharmacol Sin 30: 637-645.
58. Sathaliyawala T, Rao M, Maclean DM, Birx DL, Alving CR, et al. (2006) Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines. J Virol 80: 7688-7698.
59. Shivachandra SB, Li Q, Peachman KK, Matyas GR, Leppla SH, et al. (2007) Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine 25: 1225-1235.
60. Wu J, Tu C, Yu X, Zhang M, Zhang N, et al. (2007) Bacteriophage T4 nanoparticle capsid surface SOC and HOC bipartite display with enhanced classical swine fever virus immunogenicity: a powerful immunological approach. J Virol Methods 139: 50-60.
61. Ren ZJ, Tian CJ, Zhu QS, Zhao MY, Xin AG, et al. (2008) Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice. Vaccine 26: 1471-1481.
62. Eliasson DG, El Bakkouri K, Schon K, Ramne A, Festjens E, et al. (2008) CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26: 1243-1252.
63. Coutelier JP, van der Logt JT, Heessen FW, Warnier G, Van Snick J, (1987) IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 165: 64-69.
64. Markine-Goriaynoff D, Coutelier JP, (2002) Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants. J Virol 76: 432-435.
65. Mozdzanowska K, Maiese K, Furchner M, Gerhard W, (1999) Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 254: 138-146.
66. Mozdzanowska K, Zharikova D, Cudic M, Otvos L, Gerhard W, (2007) Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 4: 118.
67. Jegerlehner A, Wiesel M, Dietmeier K, Zabel F, Gatto D, et al. (2010) Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine 28: 5503-5512.
68. De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, et al. (2008) Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 26: 6503-6507.
69. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, et al. (2009) Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27: 6512-6521.
70. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, et al. (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13: 426-435.
71. Wu F, Yuan XY, Huang WS, Chen YH, (2009) Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine. Vaccine 27: 6095-6101.
72. Wang TT, Tan GS, Hai R, Pica N, Ngai L, et al. (2010) Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 107: 18979-18984.
73. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R, (2010) New adjuvants for human vaccines. Curr Opin Immunol 22: 411-416.
74. HogenEsch H, (2002) Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20 (Suppl 3): S34-39.
75. Aguilar JC, Rodriguez EG, (2007) Vaccine adjuvants revisited. Vaccine 25: 3752-3762.